

7 June 2019

Dear Generation Program Investigators,

Novartis would like to inform you on interim findings from an ongoing 104-week rat carcinogenicity study with CNP520 (umibecestat). **The benefit-risk profile for CNP520 remains positive, and currently, no changes are recommended for the ongoing clinical trials**

buiten reikwijdte verzoek and CCNP520A2202J).

5.1.1.c

Clinical safety data:

5.1.1.c

Sponsor Assessment:

5.1.1.c

5.1.1.c

HA notification will be issued parallel to this letter. If required, please forward this letter to your local Ethics Committee/Institutional Review Board.

Sincerely,

5.1.2.e

Novartis Pharmaceuticals

5.1.2.e

Novartis Pharma AG